HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?

Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline

By BioPharma Dive · Jun 1, 2026 · via BioPharma Dive
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
The WeekFiercePharma ↗
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already …
Jun 1, 2026
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
The WeekFierceBiotech ↗
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-s…
Jun 1, 2026
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
The WeekBriefing
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
Jun 1, 2026